Seven Grand Managers’s Relmada Therapeutics RLMD Stock Holding History

Seven Grand Managers’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.19M	Hold	315,788	–	–	0.09%	139
2026 Q1	$2.2M	Buy	+315,788	New	+$1.49M	0.15%	108

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Seven Grand Managers's RLMD Position: Q2 2026 in Review

Seven Grand Managers held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 315,788 shares worth $2.19M. The position accounts for 0.09% of the portfolio, ranked #139.

Seven Grand Managers first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.2M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Seven Grand Managers held 315,788 shares of Relmada Therapeutics worth $2.19M as of Q2 2026.
Seven Grand Managers left its Relmada Therapeutics share count unchanged in Q2 2026.
Relmada Therapeutics made up 0.09% of Seven Grand Managers's portfolio in Q2 2026, its #139 holding.
Seven Grand Managers first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
Seven Grand Managers's Relmada Therapeutics position peaked at $2.2M in Q1 2026.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.